stent clinical trials results

12 months dual antiplatelet versus 6 months dual antiplatelet
ISAR-SAFE, 2009 NCT00661206	additional 6 month period of clopidogrel versus placebo	Patients on clopidogrel therapy at least 6 months after DES implantation, who do not require a reintervention	double blind Follow-up duration: 12 months
24 months of dual antiplatelet treatment versus 6 months dual antiplatelet
PRODIGY, 2011 NCT00611286	24 months of dual antiplatelet treatment (clopidogrel plus aspirin) versus 6 months of dual antiplatelet treatment (clopidogrel plus aspirin)	patients (74 with acute coronary syndromes and 26 with stable angina) who underwent stenting	open Follow-up duration: 2 years
3 months DAPT versus 12 months DAPT
OPTIMIZE, 2013 NCT01113372	3 months DAPT (aspirin (100-200 mg daily) and clopidogrel (75 mg daily)) versus 12 months DAPT	patients with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents	open-label Brazil
6-month dual antiplatelet therapy versus 12 months dual antiplatelet
EXCELLENT, 2011 NCT00698607	dual antiplatelet therapy for six months versus dual antiplatelet therapy for one year	patients with coronary artery disease
cilostazol versus aspirin
Kunishima, 1997	Cilostazol 200 mg qD unspecified durationg qD versus Aspirin 81 mg qD
cilostazol + aspirin versus aspirin
Sekiya, 1998	Cilostazol 200 mg qD x6mos Aspirin 81 mg qD versus Coumadin unspecified regimen Aspirin 81 mg qD
cilostazol + aspirin versus ticlopidine + aspirin
Kozuma, 2001	Cilostazol 200 mg qD x6 mos Aspirin 81–162 mg qD versus Ticlopidine 200 mg qD x6 mos Aspirin 81–162 mg qD
Ochiai, 1999	Cilostazol 100 mg BID x6 mos Aspirin 81 mg TID versus Ticlopidine 100 mg BID x1 mo Aspirin 81 mg TID
Park, 1999	Cilostazol 100 mg BID x6 mos Aspirin 200 mg qD versus Ticlopidine 250 mg BID x4 wks Aspirin 200 mg qD
Yoon, 1999	Cilostazol 100 mg BID x30 days Aspirin 100 mg qD versus Ticlopidine 250 mg BID x30 days Aspirin 100 mg qD
Kamishirado, 2002	Cilostazol 200 mg qD x6 mos Aspirin 81 mg qD versus Ticlopidine 200 mg qD x6 mos Aspirin 81 mg qD
clopidogrel + aspirin versus ticlopidine + aspirin
Müller, 2000	Clopidogrel 75 mg qD x4 wks Aspirin 100 mg qD versus Ticlopidine 250 mg BID x4 wks Aspirin 100 mg qD
CLASSICS, 2000	Clopidogrel 300mg x1, 75 mg qD x4 wks Aspirin 325 mg qDypñ ·` versus Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD
TOPPS, 2001	Clopidogrel 300 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD versus Ticlopidine 500 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD
Piamsomboon, 2001	Clopidogrel 300 mg x1, 75 mg qD x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD versus Ticlopidine 250 mg po BID x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD
clopidogrel+aspirin versus aspirin
REAL-LATE, ZEST-LATE, 2010 NCT00484926	clopidogrel plus aspirin versus aspirin alone	patients who had received drugeluting stents and had been free of major adverse cardiac or cerebrovascular events and major bleeding for a period of at least 12 months	open Follow-up duration: 19.2 months South Korea
Endeavor stent and three months of DAPT versus standard 12-month DAPT and other DES
RESET, NCT01145079	versus
high-dose clopidogrel versus normal-dose clopidogrel
GRAVITAS, 2011 NCT00645918	High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) versus regular clopidogrel dose	patients receiving drug-eluting stents with high residual platelet activity (PRU>=230) on the regular clopidogrel dose (platelet-function tests with the VerifyNow assay 12 to 24 hours after PCI)	open Follow-up duration: 6 months North America
prolonged dual antiplatelet therapy versus 12 months dual antiplatelet
DES-LATE, 2010 NCT00484926	dual antiplatelet therapy (clopidogrel plus aspirin) versus aspirin alone	patients who had received drug eluting stents and had been free of major adverse cardiac or cerebrovascular events and major bleeding for a period of at least 12 months	open Follow-up duration: 19.2 mo South Korea
ticlopidine + aspirin versus aspirin
STARS (vs aspirin), 1998	Ticlopidine 250 mg BID 4 wks Aspirin 325 mg qDDage/pj versus Aspirin 325 mg qD
Hall, 1996	Ticlopidine 250 mg BID 1 mo Aspirin 325 mg qD 5 days versus Aspirin 325 mg qD
ticlopidine + aspirin versus coumadin + aspirin
STARS (vs coumadin+asp), 1998	Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD versus Coumadin INR 2–2.5 x4 wks Aspirin 325 mg qDBID
FANTASTIC, 1998	Ticlopidine 250 mg BID 6 wks Aspirin 100–325 mg qD versus Coumadin INR† 2.5–3.0 6 wks Aspirin 100–325 mg qD/pj
ISAR, 1996	Ticlopidine 250 mg BID 4 wks Aspirin 100 mg BIDage/pj versus Coumadin INR 3.5–4.5 4 wks Aspirin 100 mg BID
MATTIS, 1998	Ticlopidine 250 mg BID 30 days Aspirin 250 mg qD versus Coumadin INR 2.5–3.0 x30 days Aspirin 250 mg qDg qD/pj
Foussas, 2000	Ticlopidine 500mg qD 1 mo Aspirin 325 mg qD versus Coumadin INR 2–3 x4 wks Aspirin 325 mg qDg BID
triple antiplatelet versus dual antiplatelet therapy
CILON-T, 2010	triple antiplatelet therapy with aspirin, clopidogrel, and cilostazol for 6 month versus dual antiplatelet therapy	real-world patients undergoing PCI	Follow-up duration: 6 mo
triple therapy versus dual antiplatelet therapy
WOEST, NCT00769938	oral anticoagulants, aspirin and clopidogrel versus oral anticoagulants, clopidogrel